PLIANT THERAPEUTICS, INC. Research and Development Expense
PLIANT THERAPEUTICS, INC. (PLRX) reported Research and Development Expense of $16.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $16.73M, a 48.05% decline year-over-year.
- PLIANT THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $13.58M, a 68.73% decline year-over-year.
- PLIANT THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $15.59M, a 59.83% decline year-over-year.
- PLIANT THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $17.94M, a 62.44% decline year-over-year.
- PLIANT THERAPEUTICS, INC. research and development expense for fiscal 2025 was $109.16M, a 35.53% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. research and development expense for fiscal 2024 was $169.31M, a 32.48% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. research and development expense for fiscal 2023 was $127.80M, a 31.84% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. research and development expense for fiscal 2022 was $96.94M, a 25.00% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.73M 10-Q · filed 2026-08-11 | $30.31M 10-Q · filed 2026-08-11 | $45.90M derived: sum of 3 quarters · filed 2026-08-11 | $63.83M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $13.58M 10-Q · filed 2026-05-11 | $29.17M derived: sum of 2 quarters · filed 2026-05-11 | $47.11M derived: sum of 3 quarters · filed 2026-05-11 | $79.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $15.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $33.52M derived: sum of 2 quarters · filed 2026-03-11 | $65.72M derived: sum of 3 quarters · filed 2026-08-11 | $109.16M 10-K · filed 2026-03-11 |
| 2025-09-30 | $17.94M 10-Q · filed 2025-11-06 | $50.14M derived: sum of 2 quarters · filed 2026-08-11 | $93.57M 10-Q · filed 2025-11-06 | $132.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $32.20M 10-Q · filed 2026-08-11 | $75.63M 10-Q · filed 2026-08-11 | $114.43M derived: sum of 3 quarters · filed 2026-08-11 | $162.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $43.44M 10-Q · filed 2026-05-11 | $82.23M derived: sum of 2 quarters · filed 2026-05-11 | $129.98M derived: sum of 3 quarters · filed 2026-05-11 | $175.60M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $38.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $86.55M derived: sum of 2 quarters · filed 2026-03-11 | $132.16M derived: sum of 3 quarters · filed 2026-03-11 | $169.31M 10-K · filed 2026-03-11 |
| 2024-09-30 | $47.75M 10-Q · filed 2025-11-06 | $93.37M derived: sum of 2 quarters · filed 2025-11-06 | $130.52M 10-Q · filed 2025-11-06 | $163.70M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $45.62M 10-Q · filed 2025-08-07 | $82.76M 10-Q · filed 2025-08-07 | $115.95M derived: sum of 3 quarters · filed 2025-08-07 | $148.28M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $37.15M 10-Q · filed 2025-05-08 | $70.33M derived: sum of 2 quarters · filed 2025-05-08 | $102.67M derived: sum of 3 quarters · filed 2025-05-08 | $135.67M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $33.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $65.52M derived: sum of 2 quarters · filed 2025-03-03 | $98.52M derived: sum of 3 quarters · filed 2025-03-03 | $127.80M 10-K · filed 2025-03-03 |
| 2023-09-30 | $32.34M 10-Q · filed 2024-11-07 | $65.34M derived: sum of 2 quarters · filed 2024-11-07 | $94.61M 10-Q · filed 2024-11-07 | $119.73M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $33.00M 10-Q · filed 2024-08-07 | $62.27M 10-Q · filed 2024-08-07 | $87.39M derived: sum of 3 quarters · filed 2025-03-03 | $112.00M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $29.27M 10-Q · filed 2024-05-06 | $54.39M derived: sum of 2 quarters · filed 2025-03-03 | $78.99M derived: sum of 3 quarters · filed 2025-03-03 | $105.33M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $25.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $49.72M derived: sum of 2 quarters · filed 2025-03-03 | $76.06M derived: sum of 3 quarters · filed 2025-03-03 | $96.94M 10-K · filed 2025-03-03 |
| 2022-09-30 | $24.61M 10-Q · filed 2023-11-09 | $50.94M derived: sum of 2 quarters · filed 2023-11-09 | $71.82M 10-Q · filed 2023-11-09 | $90.57M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $26.34M 10-Q · filed 2023-08-09 | $47.22M 10-Q · filed 2023-08-09 | $65.97M derived: sum of 3 quarters · filed 2024-02-27 | $87.02M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $20.88M 10-Q · filed 2023-05-09 | $39.63M derived: sum of 2 quarters · filed 2024-02-27 | $60.69M derived: sum of 3 quarters · filed 2024-02-27 | $79.90M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $18.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $39.80M derived: sum of 2 quarters · filed 2024-02-27 | $59.02M derived: sum of 3 quarters · filed 2024-02-27 | $77.55M 10-K · filed 2024-02-27 |
| 2021-09-30 | $21.05M 10-Q · filed 2022-11-08 | $40.27M derived: sum of 2 quarters · filed 2022-11-08 | $58.80M 10-Q · filed 2022-11-08 | $76.65M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $19.22M 10-Q · filed 2022-08-08 | $37.74M 10-Q · filed 2022-08-08 | $55.60M derived: sum of 3 quarters · filed 2022-08-08 | $72.48M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $18.53M 10-Q · filed 2022-05-09 | $36.38M derived: sum of 2 quarters · filed 2022-05-09 | $53.27M derived: sum of 3 quarters · filed 2022-05-09 | $70.80M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $17.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $34.74M derived: sum of 2 quarters · filed 2022-03-01 | $52.27M derived: sum of 3 quarters · filed 2022-03-01 | $66.19M 10-K · filed 2022-03-01 |
| 2020-09-30 | $16.88M 10-Q · filed 2021-11-09 | $34.42M derived: sum of 2 quarters · filed 2021-11-09 | $48.34M 10-Q · filed 2021-11-09 | $60.07M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $17.54M 10-Q · filed 2021-08-09 | $31.45M 10-Q · filed 2021-08-09 | $43.18M derived: sum of 3 quarters · filed 2022-03-01 | $53.96M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $13.92M 10-Q · filed 2021-05-10 | $25.65M derived: sum of 2 quarters · filed 2022-03-01 | $36.42M derived: sum of 3 quarters · filed 2022-03-01 | $49.52M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $11.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $22.51M derived: sum of 2 quarters · filed 2022-03-01 | $35.60M derived: sum of 3 quarters · filed 2022-03-01 | $47.35M 10-K · filed 2022-03-01 |
| 2019-09-30 | $10.78M 10-Q · filed 2020-11-10 | $23.88M derived: sum of 2 quarters · filed 2020-11-10 | $35.63M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $13.10M 10-Q · filed 2020-08-11 | $24.85M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |